Join
Live feed
·
PRReleasevia Quantisnow
BioNTech SE logo

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

ByQuantisnow·Wall Street's wire, on your screen.
BNTX· BioNTech SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BNTX (BioNTech SE) and more on Quantisnow.